[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"David D'Alessio, M.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100610188","phase-1-role-of-alpha-to-beta-cell-communication-to-adapt-insulin-secretion-to-insulin-resistance-100610188",false,"NCT07224334","Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.","Alpha to Beta Cell Communication in Health and Disease","UPGRADE","Aim 2A: Inclusion Criteria:\n\n* Age 18-45\n* Body Mass Index (BMI) \\\u003C 27.0\n* Fasting plasma glucose of ≤ 95 mg\u002FdL or HbA1c value ≤ 5.8% as measured at screening visit\n\nExclusion Criteria:\n\n* Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders\n* Personal history of diabetes or pancreatitis\n* Personal history of cardiac, gastrointestinal, renal or liver disease\n* Immediate family history of diabetes\n* Renal insufficiency (eGFR \\\u003C 60 mL\u002Fkg\u002Fmin)\n* Anemia (hematocrit \\\u003C 34%) as measured at screening visit\n* Pregnant females\n* Poor vein access\n* Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)\n* Apparent sensitivity to the study peptide as determined by the skin test\n\nAim 2B: Inclusion Criteria:\n\n* Age 35-60\n* Body Mass Index (BMI) ≥ 27.0\n* Fasting plasma glucose of \\\u003C 126 mg\u002FdL or HbA1c value \\\u003C 6.5% as measured at screening visit\n\nExclusion Criteria:\n\n* Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders\n* Personal history of diabetes or pancreatitis\n* Personal history of cardiac, gastrointestinal, renal or liver disease\n* Immediate family history of diabetes\n* Renal insufficiency (eGFR \\\u003C 60 mL\u002Fkg\u002Fmin)\n* AST and\u002For ALT levels \\> 3x the upper limit of the normal range\n* Anemia (hematocrit \\\u003C 34%) as measured at screening visit\n* Pregnant females\n* Poor vein access\n* Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)\n* Apparent sensitivity to the study peptide as determined by the skin test",true,"ALL","18 Years","60 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects.\n\nThis protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.",[29],"Diabetes (DM)",[31,32,33,34],"insulin secretion","insulin sensitivity","GLP-1","alpha- to beta-cell communication","RECRUITING","2026-02-03",{"date":38,"type":39},"2026-02-05","ACTUAL",{"date":41,"type":39},"2025-12-30",{"date":43,"type":23},"2027-12",{"name":45,"class":46},"David D'Alessio, M.D.","OTHER",""]